Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

Last updated: March 14, 2025
Sponsor: House Ear Institute
Overall Status: Active - Not Recruiting

Phase

4

Condition

Low Blood Pressure (Hypotension)

Hearing Loss

Allergy

Treatment

Montelukast

Placebo

Clinical Study ID

NCT04815187
20203338
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults 18 years of age or older

  • Must meet all AAO-HNS 2020 criteria for definite or probable Meniere's Disease

  • Must have a skin test positive for allergy

  • Is already a candidate for treatment with montelukast for allergic rhinitis/failedfirst line over-the-counter allergy treatments

Exclusion

Exclusion Criteria:

  • Had a previous surgical procedure for treatment of vertigo

  • Currently receiving any allergy immunotherapy or taking montelukast or abeta-blocker

  • Pregnant or recent pregnancy ((≤ 8 weeks postpartum), or lactation)

  • Current hospitalization for any reason

  • Any active, acute, or chronic pulmonary disorder other than asthma

  • History of intubation for asthma

Study Design

Total Participants: 39
Treatment Group(s): 2
Primary Treatment: Montelukast
Phase: 4
Study Start date:
June 07, 2021
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • House Ear Clinic

    Los Angeles, California 90057
    United States

    Site Not Available

  • House Institute Foundation

    Los Angeles, California 90057
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.